合計 50 件の最近のインサイダー取引記録が記録されています Pieris Pharmaceuticals, Inc. (PIRS), 内訳は 42 件の買い および 5 件の売り. インサイダー買い総額は $12.03M インサイダー売り総額は $2.66M.
最近活動のある主要インサイダーには Geraghty James A, Kiritsy Christopher P, Dellora Investments Lp. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — PIRS
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2024-12-12 |
Geraghty James A |
Director |
株式返還 |
1 |
$0.01 |
$0.01 |
- |
| 2024-12-02 |
Kiritsy Christopher P |
Director |
RSU 付与（制限付株式） |
500 |
$16.43 |
$8.22K |
500 |
| 2024-11-06 |
Dellora Investments Lp |
10 Percent Owner |
不明 |
- |
- |
- |
141,079 |
| 2024-08-12 |
Adar1 Capital Management, Llc |
10 Percent Owner |
情報に基づく買い |
757 |
$15.88 |
$12.02K |
15,067 |
| 2024-08-09 |
Adar1 Capital Management, Llc |
10 Percent Owner |
情報に基づく買い |
3,000 |
$14.89 |
$44.68K |
127,331 |
| 2024-08-07 |
Geraghty James A |
Director |
情報に基づく買い |
1 |
$1.00 |
$1.00 |
1 |
| 2024-07-24 |
Adar1 Capital Management, Llc |
10 Percent Owner |
不明 |
- |
- |
- |
14,310 |
| 2023-06-21 |
Geraghty James A |
Director |
RSU 付与（制限付株式） |
45,000 |
$0.26 |
$11.7K |
45,000 |
| 2023-06-21 |
Kiritsy Christopher P |
Director |
RSU 付与（制限付株式） |
40,000 |
$0.26 |
$10.4K |
40,000 |
| 2023-06-21 |
Sherman Matthew L |
Director |
RSU 付与（制限付株式） |
40,000 |
$0.26 |
$10.4K |
40,000 |
| 2023-06-21 |
Kiener Peter A |
Director |
RSU 付与（制限付株式） |
40,000 |
$0.26 |
$10.4K |
40,000 |
| 2023-06-21 |
Richman Michael |
Director |
RSU 付与（制限付株式） |
40,000 |
$0.26 |
$10.4K |
40,000 |
| 2023-06-21 |
Barbier Ann |
Director |
RSU 付与（制限付株式） |
40,000 |
$0.26 |
$10.4K |
40,000 |
| 2023-06-21 |
Said Maya R. |
Director |
RSU 付与（制限付株式） |
40,000 |
$0.26 |
$10.4K |
40,000 |
| 2023-05-25 |
Kiritsy Christopher P |
Director |
情報に基づく買い |
10,000 |
$0.85 |
$8.5K |
20,000 |
| 2023-05-11 |
Bvf Partners L P/il |
10 Percent Owner |
処分 |
265,000 |
$7.10 |
$1.88M |
- |
| 2023-02-24 |
Yoder Stephen S. |
Chief Executive Officer |
RSU 付与（制限付株式） |
634,021 |
$1.39 |
$881.29K |
634,021 |
| 2023-02-24 |
Bures Thomas |
Chief Financial Officer |
RSU 付与（制限付株式） |
249,080 |
$1.39 |
$346.22K |
249,080 |
| 2023-02-24 |
Kaufmann Hitto |
Chief Scientific Officer |
RSU 付与（制限付株式） |
249,080 |
$1.39 |
$346.22K |
249,080 |
| 2023-02-24 |
Olwill Shane |
Chief Development Officer |
RSU 付与（制限付株式） |
249,080 |
$1.39 |
$346.22K |
249,080 |
| 2023-02-24 |
Mousa Ahmed |
Chief Business Officer |
RSU 付与（制限付株式） |
249,080 |
$1.39 |
$346.22K |
249,080 |
| 2022-06-22 |
Geraghty James A |
Director |
RSU 付与（制限付株式） |
45,000 |
- |
- |
45,000 |
| 2022-06-22 |
Kiritsy Christopher P |
Director |
RSU 付与（制限付株式） |
40,000 |
$1.82 |
$72.8K |
40,000 |
| 2022-06-22 |
Sherman Matthew L |
Director |
RSU 付与（制限付株式） |
40,000 |
- |
- |
40,000 |
| 2022-06-22 |
Kiener Peter A |
Director |
RSU 付与（制限付株式） |
40,000 |
- |
- |
40,000 |
| 2022-06-22 |
Richman Michael |
Director |
RSU 付与（制限付株式） |
40,000 |
- |
- |
40,000 |
| 2022-06-22 |
Barbier Ann |
Director |
RSU 付与（制限付株式） |
40,000 |
$1.82 |
$72.8K |
40,000 |
| 2022-06-22 |
Said Maya R. |
Director |
RSU 付与（制限付株式） |
40,000 |
- |
- |
40,000 |
| 2022-05-13 |
Demuth Tim |
Chief Medical Officer |
情報に基づく買い |
6,000 |
$1.71 |
$10.26K |
6,000 |
| 2022-02-22 |
Yoder Stephen S. |
Chief Executive Officer |
RSU 付与（制限付株式） |
625,874 |
$3.03 |
$1.9M |
625,874 |
| 2022-02-22 |
Bures Thomas |
Chief Financial Officer |
RSU 付与（制限付株式） |
215,819 |
$3.03 |
$653.93K |
215,819 |
| 2022-02-22 |
Kaufmann Hitto |
SVP, Chief Scientific Officer |
RSU 付与（制限付株式） |
215,819 |
$3.03 |
$653.93K |
215,819 |
| 2022-02-22 |
Demuth Tim |
Chief Medical Officer |
RSU 付与（制限付株式） |
100,000 |
$3.03 |
$303K |
100,000 |
| 2022-02-22 |
Olwill Shane |
Chief Development Officer |
RSU 付与（制限付株式） |
215,819 |
$3.03 |
$653.93K |
215,819 |
| 2022-02-22 |
Mousa Ahmed |
Chief Business Officer |
RSU 付与（制限付株式） |
215,819 |
$3.03 |
$653.93K |
215,819 |
| 2021-10-06 |
Mousa Ahmed |
Chief Business Officer |
処分 |
150,000 |
$2.50 |
$375K |
- |
| 2021-08-30 |
Olwill Shane |
Chief Development Officer |
情報に基づく売り |
29,200 |
$5.15 |
$150.38K |
4,638 |
| 2021-08-01 |
Demuth Tim |
Officer |
不明 |
- |
- |
- |
- |
| 2021-08-01 |
Demuth Tim |
Chief Medical Officer |
RSU 付与（制限付株式） |
360,000 |
$3.48 |
$1.25M |
360,000 |
| 2021-08-01 |
Olwill Shane |
Chief Development Officer |
処分 |
82,000 |
$3.09 |
$253.38K |
- |
| 2021-06-25 |
Geraghty James A |
Director |
RSU 付与（制限付株式） |
45,000 |
$4.00 |
$180K |
45,000 |
| 2021-06-25 |
Kiritsy Christopher P |
Director |
RSU 付与（制限付株式） |
40,000 |
$4.00 |
$160K |
40,000 |
| 2021-06-25 |
Sherman Matthew L |
Director |
RSU 付与（制限付株式） |
40,000 |
$4.00 |
$160K |
40,000 |
| 2021-06-25 |
Kiener Peter A |
Director |
RSU 付与（制限付株式） |
40,000 |
$4.00 |
$160K |
40,000 |
| 2021-06-25 |
Richman Michael |
Director |
RSU 付与（制限付株式） |
40,000 |
$4.00 |
$160K |
40,000 |
| 2021-06-25 |
Barbier Ann |
Director |
RSU 付与（制限付株式） |
40,000 |
$4.00 |
$160K |
40,000 |
| 2021-06-25 |
Said Maya R. |
Director |
RSU 付与（制限付株式） |
40,000 |
$4.00 |
$160K |
40,000 |
| 2021-03-04 |
Yoder Stephen S. |
Chief Executive Officer |
RSU 付与（制限付株式） |
530,000 |
$2.50 |
$1.33M |
530,000 |
| 2021-03-04 |
Bures Thomas |
Vice President, Finance |
RSU 付与（制限付株式） |
150,000 |
$2.50 |
$375K |
150,000 |
| 2021-03-04 |
Kaufmann Hitto |
SVP, Chief Scientific Officer |
RSU 付与（制限付株式） |
220,000 |
$2.50 |
$550K |
220,000 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
